Oncogenesis: Scientists have developed a research model for acute myeloid leukemia in young children that is expected to help develop new targeted therapies!

The researchers developed an engineered clinically relevant t(7; 12) Acute myeloid leukemia models, which may help reveal molecular targets
that can be targeted by the disease.

Acute myeloid leukemia is a high-risk cancer that affects children under two years of age, and scientists first identified specific biomarkers
associated with this cancer about 20 years ago 。 Recently, an article published in the international journal Oncogenesis titled "Engineered model of t(7; 12)(q36; p13) AML recapitulates patient-specific features and gene expression profiles", scientists from Brunel University and other institutions have made great progress
in the research and development of treatments for infantile leukemia.

When researchers use genetic engineering to replicate genetic defects in diseases, babies with leukemia may be able to get a range of new treatments; For the first time, the researchers used genetic engineering to create a failure model, meaning they could study the biological mechanisms of infantile leukemia to reveal potential drug targets
.
Researcher Sabrina Tosi said this is a key step in finding a cure for rare and lethal forms of childhood leukemia, and by generating in vitro models of this type of leukemia, researchers can provide tools for further investigation, which may help them identify potential pharmaceutical targets that could help develop possible new therapies
.

Around 100 children in the UK are diagnosed with acute myeloid leukaemia each year, and there is no single preferred treatment, clinicians try different combinations of chemotherapy and bone marrow stem cell transplantation, and almost no young children survive more than 3 years
。 As early as 2000, researchers found that there are products of high levels of MNX1 gene expression in infants with acute myeloid leukemia who carry specific gene mutations, but because the disease mainly affects infants, it is difficult for researchers to collect enough cancer cells from patients to study, so researchers know little
about how genes work 。 Researchers have used gene editing to create special cell models that contain mutations in genes that produce MNX1 in excess so that the model can be made over and over again, meaning scientists can now focus on this type of leukemia to see how it works at the molecular level to help develop new therapies
.

Scientists have developed a research model for acute myeloid leukemia in young children, which is expected to help develop new targeted therapies
.

Image credit: Oncogenesis (2022).
DOI: 10.
1038/s41389-022-00426-2

Thanks to recent advances in genomic engineering, they have now developed novel mouse and human research models, and the mechanisms by which leukemia occurs are only now slowly being unraveled, including the exact window of the impact and the role of MNX1, understanding chromosomal translocation t (7; 12) cytogenetic, molecular, and clinical features may pave the way
for the development of targeted therapies.
In children, where standard of care is now essentially the same as in adults, chemotherapy and, in some cases, stem cell transplants, the researchers hope to identify targets that are very specific to specific types of leukemia so that more effective and less invasive therapies
can be developed.

In summary, in this study, the researchers developed an engineered clinically relevant t(7; 12) Acute myeloid leukemia models, which may help reveal molecular targets
that can be targeted by the disease.
(Bio Valley Bioon.
com)

Original source:

Ragusa, D.
, Cicirò, Y.
, Federico, C.
et al.
Engineered model of t(7; 12)(q36; p13) AML recapitulates patient-specific features and gene expression profiles.
Oncogenesis 11, 50 (2022).
doi：10.
1038/s41389-022-00426-2